Background: In 2010-2011, the KRAK study on the diagnostic effectiveness of the new Polish Baseline Series (POL-1000) for patch testing was carried out in 11 allergy and dermatology centres across Poland. The new series was introduced in June 2010 and consisted of European Baseline Series supplemented with palladium and propolis - two sensitisers that seemed frequent and relevant in Poland. Altogether 624 patients were included. At least one positive reaction was recorded in 59.3% patients, and in 40.9% at least one was deemed clinically relevant (higher rates were recorded in children and adolescents: 65.4% and 46.5%, respectively). The two additions to the series - palladium and propolis have proven their importance: palladium gave positive reactions in 11.4% of patients, including 4.2% considered clinically relevant (rank 4 among most frequent sensitisers), for propolis, the respective figures were 4.6%; and 1.4% (rank 8).
The present Phase 2 study, is aimed at testing a broader series of candidate haptens in order to further improve the diagnostic effectiveness of the baseline series.
Methods: In the Phase 2 Study (KRAK2), Polish Baseline Series has been supplemented with 20 additional hapten preparations. The selection was made based upon results of pilot studies, search of emerging sensitisers in literature and analysing exposures to them in Poland, as well as generous advice of patch test experts throughout Europe.
Results: A listing of the study series has been devised consisting of 50 tests substances, and the final series was produced by Chemotechnique Diagnostics (Sweden). The KRAK2 series was distributed to nine participating allergy and dermatology centres - from university clinics to private practices. In this way, a good representation of various patient groups was sought for, including the social status, age and gender.
Conclusion: This ongoing study demonstrates both the potential for, and benefit from the collaboration between allergists and dermatologists - two specialties that seem equally interested in allergic contact dermatitis and may learn a great deal from each other.
© Radoslaw Spiewak (contact).
This page is part of the www.RadoslawSpiewak.net website.
Document created: 29 May 2017, last updated: 30 May 2017.